Where does immunotherapy actually cure cancer?
Immunotherapy has achieved durable cures in specific, often rare, situations. The strongest evidence comes from a 2023 study of 33 patients with multi-drug resistant blood cancers (leukemia, lymphoma, multiple myeloma) who received a novel immunotherapy using pre-activated donor immune cells. Complete remission occurred in 23 out of 33 patients (70%), and six patients remained cancer-free for over five years, with the first patient now 30 years out with no further treatment — essentially cured [4]. This shows that in certain blood cancers, especially when the tumor burden is low, immunotherapy can be curative.
In solid tumors, the picture is more limited. A 2020 study of patients with advanced kidney, bladder, and prostate cancers starting immunotherapy found that durable complete responses (meaning no detectable cancer long-term) occur in fewer than 10% of patients [1]. Even among those who respond, only about 20% have to stop treatment due to severe side effects [2]. So while cures do happen, they are the exception, not the rule.
Why doesn't immunotherapy work for most cancers?
The main reason is that tumors actively suppress the immune system. A 2022 review on pancreatic cancer — one of the deadliest — explains that this cancer creates a uniquely immunosuppressive tumor microenvironment that blocks immune cells from attacking it. Despite promising lab results, nearly all immunotherapy trials in pancreatic cancer have failed, except for a tiny minority of patients with specific genetic markers [6]. This is a pattern seen across many hard-to-treat cancers: the tumor builds a fortress that immunotherapy cannot penetrate.
Another key factor is that immunotherapy only works well in tumors with many genetic mutations (high tumor mutational burden), which produce abnormal proteins (neoantigens) that the immune system can recognize. Only about 10–40% of cancer patients have tumors with enough of these targets to benefit from current immune checkpoint inhibitors [2]. For the rest, the cancer simply looks too 'normal' for the immune system to see it as a threat. Researchers are now exploring ways to make these 'cold' tumors 'hot' by combining immunotherapy with other treatments like chemotherapy, radiation, or nanotechnology [3][5].
What do patients actually expect from immunotherapy?
There is a significant gap between what immunotherapy can deliver and what patients believe it will deliver. A 2020 study of 60 patients with advanced genitourinary cancers found that despite extensive counseling from their oncologists, 23% of patients had inaccurate expectations about the potential benefit of immunotherapy — they believed it was more likely to cure them than the evidence supports [1]. Interestingly, patients with more realistic expectations reported lower anxiety scores, suggesting that honest communication about the limits of immunotherapy may actually improve emotional well-being [1].
This mismatch matters because it affects treatment decisions and satisfaction. The same study found no difference in quality of life or depression between those with accurate versus inaccurate expectations, but the anxiety link is important [1]. For patients considering immunotherapy, understanding that it is not a guaranteed cure — but can be life-extending or even curative in a minority — allows for more informed choices and better psychological adjustment.
About These Sources
This answer is built on 6 peer-reviewed studies — published from 2020 to 2024, 1 from 2024 or later, 3 in Q1 journals, collectively cited 241 times — selected as the most relevant from 11 studies that passed quality screening, drawn from 90 papers retrieved from a database of over 500 million.
Sources used in this answer
Perception of cure among patients with metastatic genitourinary cancer initiating immunotherapy.
In a cross-sectional survey of 60 patients with advanced genitourinary cancers starting immunotherapy, durable complete responses occur in fewer than 10% of patients, yet 23% of patients had inaccurate expectations of cure despite counseling; those with accurate expectations reported lower anxiety.
Cancer neoantigens as potential targets for immunotherapy
A review of immune checkpoint inhibitors reports that only 10–40% of cancer patients benefit from these drugs, and about 20% discontinue treatment due to severe immune-related side effects; high tumor mutational burden is a key biomarker for response.
Enhancing cancer immunotherapy: Nanotechnology-mediated immunotherapy overcoming immunosuppression
A review of nanotechnology-mediated immunotherapy highlights that most patients do not benefit from current immunotherapy due to the immunosuppressive tumor microenvironment, and nanomedicines are being designed to target immune cells to improve responses.
Immunotherapy with cure potential of multi-drug resistant hematologic malignancies using IL-2 preactivated intentionally mismatched donor lymphocyte
In a study of 33 patients with multi-drug resistant blood cancers treated with pre-activated donor immune cells, 23 (70%) achieved complete remission, 6 remained cancer-free for over 5 years, and the first patient is 30 years out with no further treatment, suggesting cure is possible in this setting.
The right Timing, right combination, right sequence, and right delivery for Cancer immunotherapy
A review emphasizes that the types of cancer benefiting from immune checkpoint inhibitors are limited, and that optimal timing, combination, sequence, and delivery of immunotherapy are critical to expanding its efficacy.
Facts and Hopes in Immunotherapy of Pancreatic Cancer
A review of immunotherapy in pancreatic cancer states that despite revolutionizing treatment of other solid tumors, immunotherapy has made few inroads in pancreatic cancer due to its immunosuppressive microenvironment; most trials have failed except in a small minority with selected biomarkers.